- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02172339
The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects
The Pharmacokinetic, Safety and Tolerability of Tiotropium (4.8 mcg, Single i.v. Dose) in Outpatients With Renal Impairment in Comparison to Healthy Subjects (Open Label, Group Comparison, Two-center Study)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Subjects:
Subject with normal renal function ( creatinine clearance of 80% of predicted creatinine clearance in healthy volunteers), as confirmed by normal physical examination including vital signs, ECG and laboratory values
Calculated creatinine clearance (male);
= ((140 - age(yr)) x (Wt (kg))) / (72 x predicted serum creatinine (mg/dL))
Calculated creatinine clearance (female);
= ((140 - age(yr)) x (Wt(kg))) / (85 x predicted serum creatinine (mg/dL))
- Subject with impaired renal function must be of age related good health and without clinically significant abnormalities as assessed during the physical examination. Mildly impaired renal patients were defined as those with creatinine clearance of 40 - 80% of predicted creatinine clearance; moderately impaired renal patients were defined as those with creatinine clearance of 10 - 40% of predicted creatinine clearance. Laboratory values of subjects with renal impairment could have been outside the normal range if the deviations were due to the underlying renal disease.
- Male or female, age between 40 and 70 years with normal body - weight index (+/- 25%, Broca-index)
- Subjects with normal 12 - lead ECG recording
- Subjects with normal physical examination
- Subjects with normal clinical and laboratory tests (except for indicators of renal impairment)
- Female of child bearing potential must have a negative pregnancy test
- All subjects must have a negative HIV-Ab test and negative Hepatitis B test
- All subjects must have a negative drug screening
- All subjects must sign a written informed consent prior to enrollment
Exclusion Criteria:
- Subjects with a history of more then moderate alcohol consumption (more than 1 litre of beer per day or the equivalent amount of alcohol in any other alcoholic beverage, approximately 50 g of alcohol per day). 24 hours before dosing and 24 hours post dosing, alcohol was not permitted
- Present or past participation in a drug detoxification program
- Smokers
- Subjects requiring any concomitant medication not compatible with this study
- Subjects with hypotension (systolic blood pressure less than 100 mmHg, diastolic less than 60 mmHg) or hypertension (systolic blood pressure more than 165 mmHg or diastolic more than 100 mmHg) under adequate medication
- Subjects who participated in a clinical trial of any other investigational drug within two months prior to the start of this study
- Pregnant or lactating women or women of child bearing potential not using a medically approved means contraception. (i.e., oral contraceptives, intrauterine devices, diaphragm)
- Subjects who donated blood within three months prior to the start of the study
- Subjects with a history of chronic or recurrent convulsive disorders or ongoing hepatic dysfunction
- Subjects with ongoing acute systemic illness or recovery from acute systemic illness
- Subjects with a history of cancer within the last five years
- Subjects with known hypersensitivity to anticholinergic drugs
- Subjects with known symptomatic prostatic hypertrophy or bladder neck obstruction
- Subjects with known narrow-angle glaucoma
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Tiotropium
group comparison (healthy, renal impairment)
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Area under the curve (AUC (0-4h) of plasma levels of tiotropium after dosing)
Tidsramme: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
Renal clearance of tiotropium (CLren )
Tidsramme: Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1
|
Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1
|
Terminal half-life of tiotropium
Tidsramme: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
Urinary excretion (0-4h) of tiotropium, Ae 0-4h
Tidsramme: Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1
|
Day 1, 2, 3, 7, 11, 15, 18, 22 and 25 (0-4h, 4-8h), additionally -4 -0 h on day 1
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Change from baseline in Pulse Rate (PR)
Tidsramme: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
Change from baseline in Blood pressure (BP)
Tidsramme: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
Number of Participants with Serious and Non-Serious Adverse Events
Tidsramme: up to day 25
|
up to day 25
|
Change from baseline in electrocardiogram (ECG)
Tidsramme: baseline, day 1, 2, 7, 15 and 25
|
baseline, day 1, 2, 7, 15 and 25
|
Maximum measured concentration of the analyte in plasma (Cmax )
Tidsramme: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
Time from dosing to the maximum concentration of the analyte in plasma (tmax)
Tidsramme: pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
pre-dose, 7, 15 , 20, 25, 35, 45 minutes and 1, 2, 4 and 8 hours after drug administration
|
Change in FEV1 (Forced expiratory volume in one second)
Tidsramme: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
Change in FVC (Forced vital capacity)
Tidsramme: baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
baseline, day 1, 2, 3, 7,11, 15,18, 22 and 25
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Nyresykdommer
- Urologiske sykdommer
- Nyreinsuffisiens
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Parasympatholytika
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Kolinerge antagonister
- Kolinerge midler
- Bronkodilatatorer
- Anti-astmatiske midler
- Luftveismidler
- Tiotropiumbromid
Andre studie-ID-numre
- 205.134
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Nyreinsuffisiens
-
Universitaire Ziekenhuizen KU LeuvenFullførtForekomst av utvidet renal clearance | Risikofaktorer for økt renal clearanceBelgia
-
Andrew B AdamsBristol-Myers SquibbFullført
-
University Health Network, TorontoFullførtGlomerulær filtreringshastighet | Renal blodstrømCanada
-
Oregon Health and Science UniversityFullført
-
Erling Bjerregaard PedersenUniversity of AarhusUkjentRenal rørtransportDanmark
-
Amai Charitable TrustUkjent
-
The Methodist Hospital Research InstituteUkjentAkutt (cellulær) renal allograft avvisningForente stater
-
Universitaire Ziekenhuizen KU LeuvenUkjent
-
Medical University of ViennaFullførtAcidose, Renal Tubular
-
Medical University of ViennaFullførtGlomerulær filtreringshastighet | Fettsyrer, ikke-forestrede | Nyresirkulasjon | Renal plasmastrømØsterrike
Kliniske studier på Tiotropium, solution ampoules
-
Bausch & Lomb IncorporatedFullførtUheldig effekt av kontaktlinseløsningMalaysia
-
Milton S. Hershey Medical CenterLehigh Valley Hospital; St. Luke's Hospital, Pennsylvania; The Reading Hospital...Fullført
-
Boehringer IngelheimFullførtLungesykdom, kronisk obstruktivBelgia, Danmark, Finland, Tyskland, Nederland
-
LG ChemAvsluttetDorsalt håndvolumtapKorea, Republikken
-
Boehringer IngelheimFullført
-
Yale UniversityRekrutteringKoronar bypass-graftkirurgi | Utskifting av aortaklaffenForente stater
-
Bausch & Lomb IncorporatedFullførtKontaktlinsebrukForente stater
-
LG ChemAvsluttet
-
Zimmer BiometFullført
-
LG ChemFullførtFor å evaluere effektiviteten og sikkerheten til YVOIRE Y-Solution 720 injisert i midten av ansiktetVolumdefekter i midten av ansiktetKina